Business · Companies · 2 hrs ago
HK inno.N to sell Roche’s Cobas Click testing platform in South Korea
HK inno.N will sell Roche Diagnostics’ Cobas Click platform in South Korea under a new agreement.
The platform performs rapid tests for diabetes and cardiovascular care, including tests for blood sugar control, blood fats and inflammation.
These tests can help monitor conditions and guide care.
HK inno.N will handle domestic sales and distribution of the platform.
The deal marks the company’s entry into the medical device market.
HK inno.N plans to use its sales network, built through prescription medicines, in this new business area.
HK inno.N has signed a domestic sales agreement with Korea Roche Diagnostics for the Cobas Click point-of-care testing platform.
HK inno.N will handle sales and distribution of the platform in South Korea from November.
Cobas Click can rapidly perform tests for glycated hemoglobin, lipids and C-reactive protein.
The agreement marks HK inno.N’s entry into the medical-device market and expands its business beyond prescription medicines.
- Who
- HK inno.N and Korea Roche Diagnostics.
- What
- They signed an agreement for HK inno.N to sell and distribute the Cobas Click testing platform in South Korea.
- When
- The agreement was announced on November 2, 2026. Distribution is to begin in November.
- Where
- South Korea.
- Why
- HK inno.N plans to use its sales capabilities built through its prescription-medicine business to expand into medical devices.
This story does not have two clearly opposing sides.
HK inno.N announced that it had signed a domestic sales agreement with Korea Roche Diagnostics for Cobas Click.
HK inno.N is to begin sales and distribution of the platform.
- Product
- Cobas Click
- Agreement
- Domestic sales and distribution by HK inno.N
- Partner
- Korea Roche Diagnostics
- Market
- South Korea
- Tests
- Glycated hemoglobin, lipids and C-reactive protein